Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for misleading statements made during the Class Period from May 9, 2024, to May 8, 2025, which allegedly resulted in investor losses [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Iovance made false or misleading statements regarding the initiation of patient treatments at newly authorized treatment centers (ATCs) [3]. - It is alleged that Iovance's sales team and ATCs faced challenges in effectively identifying and selecting patients, leading to higher patient drop-off rates [3]. - These operational issues reportedly resulted in increased costs and reduced revenue, as ATCs could not keep pace with product manufacturing [3]. - The lawsuit contends that the positive statements made by Iovance regarding its business and outlook were materially misleading or lacked a reasonable basis [3]. Group 2: Investor Actions - Investors who purchased Iovance securities during the Class Period have until July 14, 2025, to file a lead plaintiff motion [1]. - The Portnoy Law Firm is offering complimentary case evaluations to discuss options for recovering losses [2][4].